- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Nano Interface Technology at 2005 Nanotech Venture FairMenlo Park, CA | June 21, 2005
Nano Interface Technology, Inc. (NITI) founded in 1997 has developed nanotechnology-derived economical ultra-pure coatings for orthopedic and dental implants which FDA has been in quest for many years. The NIH Nanotech review panel validates NITI's proprietary technology by stating excellent quality of the product and its enormous clinical benefits. For the last 20 years, the lifespan of orthopedic and dental implants has been 12 years with revision rate of 17%. The current coating technology can provide only 30%-66% pure coatings which increases lifespan to 12-15 years and costs twice of the noncoated implants. Therefore, currently available coated-implants are not very successful against noncoated implants. The ultra-pure coatings developed by the NITI will increase the lifespan of these implants from 12 years to 20 years or longer at lower cost resulting in significantly reduced revision. It will also reduce the use of high strength painkillers. The reduction in the revision rate of hip and knee implants from 17% to 12% has the potential of saving $825M per year in the US alone. Since this material is currently used in coating of implants, therefore implants developed using this purer material will easily get FDA approval without any clinical studies. It will be widely accepted by the consumers because the cost of these implants will be significantly lower than the existing cost of such implants.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Nanion Technologies Appoints James Costantin as Director of Customer Relations: Nanion is pleased to announce the appointment of Dr. James Costantin as Director of Customer Relations at Nanion Technologies Inc. March 31st, 2015
Prototype 'nanoneedles' generate new blood vessels in mice: Scientists have developed tiny 'nanoneedles' that have successfully prompted parts of the body to generate new blood vessels, in a trial in mice March 31st, 2015
So, near and yet so far: Stable HGNs for Raman April 1st, 2015